Reply: Thymopoiesis, inflamm-aging, and COVID-19 phenotype

Reply: Thymopoiesis, inflamm-aging, and COVID-19 phenotype

Bibliographic Details
Main Author:	Chih-Jung Chen
Format:	Article
Language:	English
Published:	Elsevier 2020-06-01
Series:	Pediatrics and Neonatology
Online Access:	http://www.sciencedirect.com/science/article/pii/S1875957220300644

Similar Items

Thymopoiesis and regulatory T cells in healthy children and adolescents
by: Maria Izabel Arismendi, et al.
Published: (2012-01-01)

Thymic Extracellular Matrix in the Thymopoiesis: Just a Supporting?
by: Marvin Paulo Lins
Published: (2022-07-01)

Thymopoiesis in Pre- and Post-Hematopoietic Stem Cell Transplantation
by: Luis Klaus A. da Rocha, et al.
Published: (2018-09-01)

Thymic Epithelial Cells Contribute to Thymopoiesis and T Cell Development
by: Hong-Xia Wang, et al.
Published: (2020-01-01)

Retinoic acid signaling in thymic epithelial cells regulates thymopoiesis
by: Wendland, K, et al.
Published: (2018)

Thymic epithelial cell support of thymopoiesis does not require Klotho
by: Xing, Y, et al.
Published: (2018)

THYMOPOIESIS INTENSITY IN PATIENTS WITH BRONCHIAL ASTHMA, DEPENDING ON DURATION OF THE DISEASE
by: E. A. Blinova, et al.
Published: (2014-07-01)

Sustained thymopoiesis and improvement in functional immunity induced by exogenous KGF administration in murine models of aging.
by: Min, D, et al.
Published: (2007)

Distinct roles of Cdc42 in thymopoiesis and effector and memory T cell differentiation.
by: Fukun Guo, et al.
Published: (2011-03-01)

Interleukin-21 promotes thymopoiesis recovery following hematopoietic stem cell transplantation
by: Aurélie Tormo, et al.
Published: (2017-06-01)

A single-cell analysis of thymopoiesis and thymic iNKT cell development in pigs
by: Weihong Gu, et al.
Published: (2022-07-01)

Embryonic thymopoiesis is initiated by an immune-restricted lympho-myeloid progenitor independently of notch signaling
by: Luis, T, et al.
Published: (2016)

Human thymopoiesis produces polyspecific CD8+ α/β T cells responding to multiple viral antigens
by: Valentin Quiniou, et al.
Published: (2023-03-01)

Thymic Epithelial Cell Alterations and Defective Thymopoiesis Lead to Central and Peripheral Tolerance Perturbation in MHCII Deficiency
by: Francesca Ferrua, et al.
Published: (2021-06-01)

T cell progenitor therapy–facilitated thymopoiesis depends upon thymic input and continued thymic microenvironment interaction
by: Smith, M, et al.
Published: (2017)

Flt3 ligand-receptor interaction is important for maintenance of early thymic progenitor numbers in steady-state thymopoiesis.
by: Kenins, L, et al.
Published: (2010)

Workup of cerebral involvement in patients with COVID-19 – authors’ reply
by: Chi-Sheng Chen, et al.
Published: (2023-05-01)

Thymus extracellular matrix-derived scaffolds support graft-resident thymopoiesis and long-term in vitro culture of adult thymic epithelial cells
by: Asnaghi, MA, et al.
Published: (2021)

The increase in thymopoiesis following T cell progenitor therapy is dependent upon the input population and continued interaction between developing T cells and the thymic microenvironment
by: Smith, M, et al.
Published: (2016)

LENTIVIRAL TRANSDUCTION OF PRIMARY ADULT MOUSE THYMIC EPITHELIAL CELLS TO CREATE CELLS COMPETENT TO SUPPORT REGULAR THYMOPOIESIS BOTH IN VITRO AND IN VIVO
by: Bosticardo, M, et al.
Published: (2012)

mTORC1 in Thymic Epithelial Cells Is Critical for Thymopoiesis, T-Cell Generation, and Temporal Control of γδT17 Development and TCRγ/δ Recombination.
by: Hong-Xia Wang, et al.
Published: (2016-02-01)

Reply to the syndemic of “COVID-19 and tuberculosis”
by: Rajashri A Patil, et al.
Published: (2023-01-01)

Author’s Reply—Is it really COVID-19?
by: David Chang, MD, et al.
Published: (2020-07-01)

Hydroxychloroquine in hospitalized patients with Covid-19. Reply
by: Horby, P, et al.
Published: (2021)

Authors’ Reply: Vaccination, payment, and COVID-19
by: Jelena Dotlic, et al.
Published: (2021-11-01)

Reply to “Novaferon, treatment in COVID-19 patients”
by: Fang Zheng, et al.
Published: (2021-02-01)

Letter in Reply: COVID-19 Infection in Oman
by: Faryal Khamis, et al.
Published: (2020-09-01)

Azithromycin for mild-to-moderate COVID-19 - Authors' reply
by: Hinks, TSC
Published: (2021)

Azithromycin for mild-to-moderate COVID-19: author's reply
by: Hinks, TSC, et al.
Published: (2021)

Reply to: Trajectories of vital signs in patients with Covid-19
by: Redfern, O, et al.
Published: (2021)

WHO COVID-19 therapeutic guidelines – authors' reply
by: White, NJ, et al.
Published: (2021)

Letter in Reply: Epidemiology of COVID-19 Infection in Oman
by: Faryal Khamis, et al.
Published: (2020-11-01)

Genetic and phenotypic analysis of the causal relationship between aging and COVID-19
by: Kejun Ying, et al.
Published: (2021-10-01)

High-dose budesonide for early COVID-19 - Authors' reply
by: Hobbs, FDR, et al.
Published: (2021)

Author's reply: COVID‐19 vaccine in liver transplant recipients
by: Atsuyoshi Mita, et al.
Published: (2024-03-01)

Urticaria and COVID-19 infection: a critical appraisal-reply
by: Mohammed Shanshal
Published: (2022-04-01)

Reply to “Pityriasis rosea during COVID-19 and its pathogenesis”
by: Dillon Nussbaum, BS, et al.
Published: (2022-12-01)

Author reply to Letters to the Editor “COVID-19 pneumonia in Taiwan”
by: Shao-Chung Cheng, et al.
Published: (2020-05-01)

Cyclosporine A and COVID19 – The COQUIMA cohort – Author's reply
by: Pablo Guisado-Vasco, et al.
Published: (2021-01-01)

Reply to “‘Tolerance’ of Misused Terminology? Enforcing Standardized Phenotypic Definitions”
by: Jakob Haaber, et al.
Published: (2015-07-01)